Sunday, July 4, 2021

Takeda’s dengue vaccine bags positive long-term efficacy results




Japanese pharma company Takeda has announced that its dengue vaccine candidate TAK-003 demonstrated continued protection through three years after vaccination, regardless of previous exposure to the disease.

The Phase III TIDES trial enrolled over 20,000 healthy children and adolescents aged four to 16 years in dengue-endemic countries in Latin America and Asia.

The safety and efficacy results from the 36-month follow-up exploratory analysis of TIDES found that, through three years after vaccination, TAK-003 demonstrated overall vaccine efficacy of 62% against virologically confirmed dengue (VCD).

The jab also demonstrated 83.6% vaccine efficacy (VE) against hospitalised dengue, with 86% VE in seropositive individuals 77.1% VE in seronegative individuals.

“Our dengue vaccine candidate continued to provide protection against dengue throughout three years, and was especially robust in preventing hospitalisation,” said Derek Wallace, VP, dengue global programme leader at Takeda.

“These results reinforce my confidence that TAK-003 can help address the significant global burden of dengue,” he added.

Previously, Takeda announced that the TIDES trial met its primary endpoint of overall VE against VCD at 12 months of follow-up, as well as all secondary endpoints for which there were enough dengue cases.

The data through 36 months of follow-up from the TIDES trial has been included in regulatory submissions to the European Union in addition to dengue-endemic countries.

The results will also be part of further regulatory filings planned for 2021, including with the US Food and Drug Administration (FDA).

Dengue is a mosquito-borne viral disease that is caused by any of four dengue virus serotypes, which can all cause dengue fever or severe dengue.

The disease is ‘pandemic prone’, with outbreaks generally seen in tropical and sub-tropical areas, although recently outbreaks have been observed in parts of the continental US and Europe.



Source link

Stay Connected

1,605FansLike
11,000FollowersFollow
342FollowersFollow
775FollowersFollow

Latest Articles

Covid’s second wave proves lethal for pregnant women

At SVP Hospital in Ahmedabad – one of the major Covid-19 hospitals of the city – 148 pregnant women with Covid-19 infection were admitted...

7 Tips to Keep Your Gut Healthy

This is common to say health (and illness) starts in your gut. If you have poor gut health, you’ll experience anything from wrinkled skin, to...

SII making first batch of Covovax: Poonawalla

The first batch of Covovax, a Covid-19 vaccine developed by Novavax Inc, is being manufactured at the Serum Institute of India's Pune facility, SII...

Sputnik V is safest among all Covid-19 vaccines, no deaths recorded: Buenos Aires study

A study by the Buenos Aires Ministry of Health to monitor the safety of the Sputnik V vaccine against Covid-19 confirmed on Thursday that...

Telangana caps Covid treatment charges in private hospitals

Hyderabad: The government of Telangana on Wednesday issued orders fixing treatment and investigation charges for Covid-19 in private hospitals.The state government, which had capped...